<DOC>
	<DOC>NCT00622388</DOC>
	<brief_summary>The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant</brief_summary>
	<brief_title>Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with DLBCL and relapse after complete remission or disease progression after partial remission who are ineligible for autologous stem cell transplantation and relapse after complete remission or disease progression after partial remission following autologous stem cell transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>